Long‐term clinical experience with amplatzer ductal occluder II for closure of the persistent arterial duct in children

医学 闭塞 外科 栓塞 狭窄 肺动脉 调车 心脏病学
作者
Sok‐Leng Kang,Gareth J. Morgan,Jonathan Forsey,Andrew Tometzki,Robin P. Martin
出处
期刊:Catheterization and Cardiovascular Interventions [Wiley]
卷期号:83 (7): 1102-1108 被引量:26
标识
DOI:10.1002/ccd.25393
摘要

To describe the long-term clinical experience and follow-up with the Amplatzer Ductal Occluder II (ADO II) in children.All patients undergoing attempted transcatheter closure of patent arterial duct (PDA) with the ADO II were included. Data collected included demographic, clinical, and echocardiographic parameters.From March 2008 until March 2013, 62 patients with a median age of 1.2 years (range 0.43-11.1 years) and median weight of 9 kg (range 4.7-31.4 kg) underwent the procedure. The median measurement for minimal ductal diameter was 2.7 mm (range 1.3-5 mm). An ADO II was implanted in 60 patients (96.8%). Two patients had significant residual shunting following deployment of the ADO II and underwent closure with the Amplatzer ductal occluder I (ADO I) during the same procedure. In six patients, the initial ADO II was unsatisfactory, and after recapture a different size ADO II was deployed. Device embolization of the ADO II to the pulmonary artery occurred in 6.7% of patients. Of these, one underwent surgical closure and three were closed with an ADO I. Complete occlusion on echocardiography was noted prior to discharge in 87.5% of the deployed occluders and 100% at first follow-up. Five year follow-up (n = 25) revealed a 100% occlusion rate. There were three cases of persistent mild left pulmonary artery stenosis at long-term follow-up.The ADO II is effective for occlusion of PDA with variable anatomy from either arterial or venous approaches with a low profile delivery system. Stable occluder position is highly dependent on accurate device sizing, good quality imaging to visualize device configuration after deployment and operator experience.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
GIINJIU发布了新的文献求助10
1秒前
烟花应助筚路蓝缕采纳,获得10
1秒前
在水一方应助szh采纳,获得10
3秒前
3秒前
3秒前
李健的粉丝团团长应助zzz采纳,获得10
4秒前
彭于晏应助zzz采纳,获得10
4秒前
4秒前
汉堡包应助zzz采纳,获得20
4秒前
japil应助zzz采纳,获得40
4秒前
李健的小迷弟应助zzz采纳,获得10
5秒前
小蘑菇应助zzz采纳,获得10
5秒前
搜集达人应助zzz采纳,获得20
5秒前
无极微光应助zzz采纳,获得20
5秒前
深情安青应助zzz采纳,获得10
5秒前
CodeCraft应助zzz采纳,获得20
6秒前
6秒前
8秒前
爆米花应助sinlar采纳,获得10
8秒前
LIVE完成签到,获得积分10
8秒前
Echo完成签到,获得积分10
12秒前
wgglegg发布了新的文献求助10
12秒前
12秒前
李健应助满意宛筠采纳,获得10
13秒前
ya0701完成签到,获得积分10
13秒前
111完成签到,获得积分20
14秒前
v0id应助pu采纳,获得10
16秒前
v0id应助pu采纳,获得10
16秒前
科目三应助pu采纳,获得10
16秒前
16秒前
幸福遥完成签到,获得积分10
17秒前
WangPeidi完成签到,获得积分10
18秒前
酷波er应助zzz采纳,获得10
18秒前
无极微光应助zzz采纳,获得20
19秒前
英俊的铭应助zzz采纳,获得10
19秒前
无极微光应助zzz采纳,获得20
19秒前
小二郎应助zzz采纳,获得10
19秒前
科研通AI6.4应助廖嘉俊采纳,获得10
19秒前
无极微光应助zzz采纳,获得20
19秒前
小二郎应助zzz采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HYDROLYSE ACIDE DE QUELQUES DIOXASPIROCYCLANES 1314
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7747950
求助须知:如何正确求助?哪些是违规求助? 9296180
关于积分的说明 20233931
捐赠科研通 7329325
什么是DOI,文献DOI怎么找? 3308744
关于科研通互助平台的介绍 2460530
邀请新用户注册赠送积分活动 2320713